PMPhilippa Morgan-Jones

Philippa Morgan-Jones

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Philippa Morgan-Jones has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimation of Gait Parameters in Huntington’s Disease Using Wearable Sensors in the Clinic and Free-living Conditions

    by Manuel Lozano-García, Emer P. Doheny, Elliot Mann, Philippa Morgan-Jones, Cheney Drew, Monica Busse-Morris, Madeleine M. Lowery

    In Huntington’s disease (HD), wearable inertial sensors could capture subtle changes in motor function. However, disease-specific validation of methods is necessary. This study presents an algorithm for walking bout and gait event detection in HD using a leg-worn accelerometer, validated only in the clinic and deployed in free-living conditions. Seventeen HD participants wore shank- and thigh-worn tri-axial accelerometers, and a wrist-worn device during two-minute walk tests in the clinic, with video reference data for validation. Thirteen participants wore one of the thigh-worn tri-axial accelerometers (AP: ActivPAL4) and the wrist-worn device for 7 days under free-living conditions, with proprietary AP data used as reference. Gait events were detected from shank and thigh acceleration using the Teager-Kaiser energy operator combined with unsupervised clustering. Estimated step count (SC) and temporal gait parameters were compared with reference data. In the clinic, low mean absolute percentage errors were observed for stride (shank/thigh: 0.6/0.9%) and stance (shank/thigh: 3.3/7.1%) times, and SC (shank/thigh: 3.1%). Similar errors were observed for proprietary AP SC (3.2%), with higher errors observed for the wrist-worn device (10.9%). At home, excellent agreement was observed between the proposed algorithm and AP software for SC and time spent walking (ICC 2,1 >0.975). The wrist-worn device overestimated SC by 34.2%. The presented algorithm additionally allowed stride and stance time estimation, whose variability correlated significantly with clinical motor scores. The results demonstrate a new method for accurate estimation of HD gait parameters in the clinic and free-living conditions, using a single accelerometer worn on either the thigh or shank.


  • Open Access

    Language-Independent Acoustic Biomarkers for Quantifying Speech Impairment in Huntington's Disease

    by Vitória S. Fahed, Emer P. Doheny, Carla Collazo, Joanna Krzysztofik, Elliot Mann, Philippa Morgan-Jones, Laura Mills, Cheney Drew, Anne E. Rosser, Rebecca Cousins, et al.

    Purpose: Changes in voice and speech are characteristic symptoms of Huntington's disease (HD). Objective methods for quantifying speech impairment that can be used across languages could facilitate assessment of disease progression and intervention strategies. The aim of this study was to analyze acoustic features to identify language-independent features that could be used to quantify speech dysfunction in English-, Spanish-, and Polish-speaking participants with HD. Method: Ninety participants with HD and 83 control participants performed sustained vowel, syllable repetition, and reading passage tasks recorded with previously validated methods using mobile devices. Language-independent features that differed between HD and controls were identified. Principal component analysis (PCA) and unsupervised clustering were applied to the language-independent features of the HD data set to identify subgroups within the HD data. Results: Forty-six language-independent acoustic features that were significantly different between control participants and participants with HD were identified. Following dimensionality reduction using PCA, four speech clusters were identified in the HD data set. Unified Huntington's Disease Rating Scale (UHDRS) total motor score, total functional capacity, and composite UHDRS were significantly different for pairwise comparisons of subgroups. The percentage of HD participants with higher dysarthria score and disease stage also increased across clusters. Conclusion: The results support the application of acoustic features to objectively quantify speech impairment and disease severity in HD in multilanguage studies. Supplemental Material: https://doi.org/10.23641/asha.25447171


  • Wearable Activity Monitors to Support Physical Activity Interventions in Neurodegenerative Disease: A Feasibility Study

    by Hai-Jung Steffi Shih, Lori Quinn, Philippa Morgan-Jones, Katrina Long, Abigail R Schreier, Ciaran P Friel

    Aim: To evaluate the feasibility of using activity monitors in a physical activity (PA) intervention in people with Parkinson's (PD) and Huntington's disease (HD). Materials & methods: People with ...


  • Open Access

    Monitoring and Managing Lifestyle Behaviors Using Wearable Activity Trackers: Mixed Methods Study of Views From the Huntington Disease Community

    by Philippa Morgan-Jones, Annabel Jones, Monica Busse, Laura Mills, Philip Pallmann, Cheney Drew, Astri Arnesen, Fiona Wood, Domino-HD Consortium

    Background: There are early indications that lifestyle behaviors, specifically physical activity and sleep, may be associated with the onset and progression of Huntington disease (HD). Wearable activity trackers offer an exciting opportunity to collect long-term activity data to further investigate the role of lifestyle, physical activity, and sleep in disease modification. Given how wearable devices rely on user acceptance and long-term adoption, it is important to understand users' perspectives on how acceptable any device might be and how users might engage over the longer term. Objective: This study aimed to explore the perceptions, motivators, and potential barriers relating to the adoption of wearable activity trackers by people with HD for monitoring and managing their lifestyle and sleep. This information intended to guide the selection of wearable activity trackers for use in a longitudinal observational clinical study. Methods: We conducted a mixed methods study; this allowed us to draw on the potential strengths of both quantitative and qualitative methods. Opportunistic participant recruitment occurred at 4 Huntington's Disease Association meetings, including 1 international meeting and 3 United Kingdom-based regional meetings. Individuals with HD, their family members, and carers were invited to complete a user acceptance questionnaire and participate in a focus group discussion. The questionnaire consisted of 35 items across 8 domains using a 0 to 4 Likert scale, along with some additional demographic questions. Average questionnaire responses were recorded as positive (score>2.5), negative (score2.5, indicating a tendency toward positive opinions on wearable activity trackers, such as the devices being advantageous, easy and enjoyable to use, and compatible with lifestyle and users being able to understand the information from trackers and willing to wear them. People with HD reported a more positive attitude toward wearable activity trackers than their family members or caregivers (P=.02). A total of 15 participants participated in 3 focus groups. Device compatibility and accuracy, data security, impact on relationships, and the ability to monitor and self-manage lifestyle behaviors have emerged as important considerations in device use and user preferences. Conclusions: Although wearable activity trackers were broadly recognized as acceptable for both monitoring and management, various aspects of device design and functionality must be considered to promote acceptance in this clinical cohort.


  • Open Access

    Utilization of wearable activity monitors to support physical activity interventions in neurodegenerative diseases: a feasibility study

    by Hai-Jung Steffi Shih, Lori Quinn, Philippa Morgan-Jones, Katrina Long, Abigail R. Schreier, Ciaran P. Friel

    Purpose: To evaluate the feasibility of using wearable activity monitors as part of a physical activity (PA) intervention and describe patterns of device weartime and PA behavior in people with Parkinson (PD) and Huntington disease (HD). Materials and Methods: Secondary analyses were conducted on two pilot studies where people with early-stage PD (n=13) and HD (n=14) enrolled in a 4-month PA coaching program. Participants wore a Fitbit Charge 2 and physical and occupational therapists guided them through understanding of PA data and goal-setting to build autonomy and facilitate PA uptake. Wear time, wear habits (delineated based on nighttime wear), and activity metrics including steps, resting heart rate, and metabolic equivalent of task (MET) *minutes were analyzed. Results: Retention rate of the intervention was 85%. Participants had a mean (SD) of 92.3(9.2)% valid wear days over the intervention period. Average daily wear time was 18.4(4.5) hours, with an initial 2-week period of high wear time fluctuation. Regardless of diagnosis, day & night Fitbit wearers had more improvements in steps (d=1.02) and MET*min/week (d=0.69) compared to day-only wearers. Conclusions: Implementing wearable activity monitors in a PA coaching intervention was feasible and provided insight into longitudinal PA behavior in people with neurodegenerative diseases.


  • Open Access

    Monitoring and Managing Lifestyle Behaviors Using Wearable Activity Trackers: Mixed Methods Study of Views From the Huntington Disease Community (Preprint)

    by Philippa Morgan-Jones, Annabel Jones, Monica Busse, Laura Mills, Philip Pallmann, Cheney Drew, Astri Arnesen, Fiona Wood

    BACKGROUND There are early indications that lifestyle behaviors, specifically physical activity and sleep, may be associated with the onset and progression of Huntington disease (HD). Wearable activity trackers offer an exciting opportunity to collect long-term activity data to further investigate the role of lifestyle, physical activity, and sleep in disease modification. Given how wearable devices rely on user acceptance and long-term adoption, it is important to understand users’ perspectives on how acceptable any device might be and how users might engage over the longer term. OBJECTIVE This study aimed to explore the perceptions, motivators, and potential barriers relating to the adoption of wearable activity trackers by people with HD for monitoring and managing their lifestyle and sleep. This information intended to guide the selection of wearable activity trackers for use in a longitudinal observational clinical study. METHODS We conducted a mixed methods study; this allowed us to draw on the potential strengths of both quantitative and qualitative methods. Opportunistic participant recruitment occurred at 4 Huntington’s Disease Association meetings, including 1 international meeting and 3 United Kingdom–based regional meetings. Individuals with HD, their family members, and carers were invited to complete a user acceptance questionnaire and participate in a focus group discussion. The questionnaire consisted of 35 items across 8 domains using a 0 to 4 Likert scale, along with some additional demographic questions. Average questionnaire responses were recorded as positive (score>2.5), negative (score2.5, indicating a tendency toward positive opinions on wearable activity trackers, such as the devices being advantageous, easy and enjoyable to use, and compatible with lifestyle and users being able to understand the information from trackers and willing to wear them. People with HD reported a more positive attitude toward wearable activity trackers than their family members or caregivers (P=.02). A total of 15 participants participated in 3 focus groups. Device compatibility and accuracy, data security, impact on relationships, and the ability to monitor and self-manage lifestyle behaviors have emerged as important considerations in device use and user preferences. CONCLUSIONS Although wearable activity trackers were broadly recognized as acceptable for both monitoring and management, various aspects of device design and functionality must be considered to promote acceptance in this clinical cohort.

  • Open Access

    Objectively characterizing Huntington’s disease using a novel upper limb dexterity test

    by Samuel Woodgate, Philippa Morgan-Jones, Susanne Clinch, Cheney Drew, Rebecca Playle, Mohamed Bennasar, Yulia Hicks, Catherine Holt, Anne-Catherine Bachoud-Lévi, Renaud Massart, et al.

    Background: The Clinch Token Transfer Test (C3t) is a bi-manual coin transfer task that incorporates cognitive tasks to add complexity. This study explored the concurrent and convergent validity of the C3t as a simple, objective assessment of impairment that is reflective of disease severity in Huntington’s, that is not reliant on clinical expertise for administration. Methods: One-hundred-and-five participants presenting with pre-manifest (n = 16) or manifest (TFC-Stage-1 n = 39; TFC-Stage-2 n = 43; TFC-Stage-3 n = 7) Huntington’s disease completed the Unified Huntington’s Disease Rating Scale and the C3t at baseline. Of these, thirty-three were followed up after 12 months. Regression was used to estimate baseline individual and composite clinical scores (including cognitive, motor, and functional ability) using baseline C3t scores. Correlations between C3t and clinical scores were assessed using Spearman’s R and visually inspected in relation to disease severity using scatterplots. Effect size over 12 months provided an indication of longitudinal behaviour of the C3t in relation to clinical measures. Results: Baseline C3t scores predicted baseline clinical scores to within 9–13% accuracy, being associated with individual and composite clinical scores. Changes in C3t scores over 12 months were small ( $$\Omega$$ Ω ≤ 0.15) and mirrored the change in clinical scores. Conclusion: The C3t demonstrates promise as a simple, easy to administer, objective outcome measure capable of predicting impairment that is reflective of Huntington’s disease severity and offers a viable solution to support remote clinical monitoring. It may also offer utility as a screening tool for recruitment to clinical trials given preliminary indications of association with the prognostic index normed for Huntington’s disease.


  • An On Body Accelerometer System for streaming therapy data using COTS UHF RFID

    by Robert Horne, Philippa Jones, Paul Taylor, John Batchelor, Catherine Holt

    This paper details the use of an on body Accelerometer COTS RFID system for use in determining specific therapeutic movements, and the performance of said movements. Conventional methodologies rely on power intensive Bluetooth or Wi-Fi technologies for live communications, but this paper outlines the use of ultra-low power battery assistive passive modes on UHF RFID chips to harness sub-2mW continuous streaming of Accelerometer data.


  • Open Access

    Automated Assessment of Movement Impairment in Huntington’s Disease

    by M. Bennasar, Y. A. Hicks, S. P. Clinch, P. Jones, C. Holt, A. Rosser, M. Busse

    Quantitative assessment of movement impairment in Huntington's disease (HD) is essential to monitoring of disease progression. This paper aimed to develop and validate a novel low cost, objective automated system for the evaluation of upper limb movement impairment in HD in order to eliminate the inconsistency of the assessor and offer a more sensitive, continuous assessment scale. Patients with genetically confirmed HD and healthy controls were recruited to this observational study. Demographic data, including age (years), gender, and unified HD rating scale total motor score (UHDRS-TMS), were recorded. For the purposes of this paper, a modified upper limb motor impairment score (mULMS) was generated from the UHDRS-TMS. All participants completed a brief, standardized clinical assessment of upper limb dexterity while wearing a tri-axial accelerometer on each wrist and on the sternum. The captured acceleration data were used to develop an automatic classification system for discriminating between healthy and HD participants and to automatically generate a continuous movement impairment score (MIS) that reflected the degree of the movement impairment. Data from 48 healthy and 44 HD participants was used to validate the developed system, which achieved 98.78% accuracy in discriminating between healthy and HD participants. The Pearson correlation coefficient between the automatic MIS and the clinician rated mULMS was 0.77 with a p-value <; 0.01. The approach presented in this paper demonstrates the possibility of an automated objective, consistent, and sensitive assessment of the HD movement impairment.